# A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer

> **NCT06974929** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** HRS-6209 Capsules
- **DRUG:** Letrozole Tablets
- **DRUG:** HRS-2189 Tablets

## Key facts

- **NCT ID:** NCT06974929
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-22
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06974929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06974929, "A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06974929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*